Clinical trials: Atypical
Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
- Trial name
- NCT05364073
- Testing
- Furmonertinib
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 160 people
- Sponsor
- ArriVent BioPharma, Inc.
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Melanocytic Nevi, Melanoma (Skin Cancer)
Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions
This observational, prospective cohort study aims to evaluate the diagnostic relevance of Reflectance Confocal Microscopy (RCM) features in atypical melanocytic lesions scheduled for surgical excision, and to correlate these…
- Conditions
- Melanocytic Nevi, Melanoma (Skin Cancer), Next Generation Sequencing (NGS)
- Trial name
- NCT07277920
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Modena and Reggio Emilia
PSC
Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a rare, progressive and often fatal disease of the intrahepatic or extrahepatic bile ducts, with an estimated prevalence in Western countries of 1/10,000.
- Trial name
- CILIA (NCT06865924)
- Testing
- Use of assembloids as in vitro models to test new pharmacological approaches
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico